MediumCardiologyHeart failure with reduced ejection fraction - guideline-directed therapyca-mccqe1ca-rcpsc-im
A 60-year-old man with an ejection fraction of 30% following a myocardial infarction is clinically stable on maximally tolerated doses of an ACE inhibitor, a beta-blocker, and spironolactone. He remains mildly symptomatic (NYHA class II). According to contemporary Canadian heart failure guidance, which additional class of medication should now be routinely considered to reduce morbidity and mortality?